NervGen Pharma Corp. (NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. This news page highlights company announcements, clinical updates and capital markets developments that relate to NervGen’s progress.
Readers can find coverage of NervGen’s listing and trading on Nasdaq under the symbol NGEN, along with commentary from the company on how this listing fits into its evolution as a biopharmaceutical issuer. News items also describe the company’s clinical milestones, including data from the Phase 1b/2a CONNECT SCI Study of its lead candidate NVG-291 in individuals with chronic spinal cord injury.
The company reports that NVG-291, a subcutaneously administered neuroreparative peptide, has demonstrated durable improvements in function, independence and quality of life in chronic SCI, supported by changes in corticospinal and reticulospinal signaling. Updates on regulatory interactions, such as FDA Type C and planned End-of-Phase 2 meetings, are also reflected in NervGen’s news flow, as the company works to define the development and registration pathway for NVG-291.
Because NervGen focuses on conditions with significant unmet medical need, its news often centers on clinical trial data, regulatory designations such as FDA Fast Track and EMA Orphan Drug status for NVG-291 in spinal cord injury, and strategic steps toward late-stage development. Investors and observers can use this page to follow how NervGen describes its progress in advancing NVG-291 and its next-generation candidate NVG-300 within the broader context of neurotrauma and neurologic disease research.
NervGen (NGEN) has dosed the first participant in RESTORE, its Phase 3 registrational study of NVG-291 for chronic spinal cord injury. The study evaluates potential improvements in hand function and quality of life in people with chronic cervical motor-incomplete spinal cord injury, involving the neck region with some motor function preserved.
NervGen anticipates enrollment completion in the second half of 2027 and topline data in the first half of 2028. The company achieved FDA alignment on RESTORE’s registrational design following its End-of-Phase 2 meeting. RESTORE builds on functional improvements observed in the placebo-controlled Phase 1b/2a CONNECT SCI study. Those findings informed primary and secondary endpoint selection, treatment duration and participant-reported measures, with a focus on functional recovery and its impact on independence and quality of life.
NervGen (NGEN) will restate annual and interim financial statements to revise valuations of certain warrants and options.
The revisions cover the audited year ended December 31, 2025, and the unaudited quarter ended June 30, 2026. They are expected to reduce previously reported stock-based compensation expense and warrant liabilities, with adjustments to unrealized gains and losses on warrant derivatives. NervGen expects a lower accumulated deficit and says the non-cash changes will not affect cash and cash equivalents, cash runway, or operations. It expects to complete the restated filings as soon as feasible and remains on track to report third-quarter 2026 results.
NervGen (NGEN) will host its inaugural R&D Day webcast on Wednesday, September 30, 2026, from 10:00 a.m. to 12:00 p.m. ET.
The event will provide an in-depth review of NVG-291, covering its scientific rationale, nonclinical and translational evidence in spinal cord injury (SCI), broader therapeutic potential, clinical data from the Phase 1 program and Phase 1b/2a CONNECT SCI study in chronic cervical SCI, and the design and rationale of the Phase 3 RESTORE registrational study. Four external experts in SCI clinical care, outcome assessment, translational research and community advocacy will join NervGen management for presentations and a live Q&A, with a webcast and replay available via the company’s website.
NervGen (NASDAQ:NGEN) reported second quarter 2026 results and business updates, highlighting progress toward its Phase 3 RESTORE trial of NVG-291 in chronic spinal cord injury (SCI). Site activation and screening are expected to begin in September 2026, with first dosing anticipated shortly thereafter and enrollment completion targeted for 2H 2027, followed by topline data in 1H 2028.
The company ended June 30, 2026 with C$86.8 million (US$61.1 million) in cash and cash equivalents, up from C$22.1 million at year-end 2025, and believes this will fund operations through the RESTORE topline readout. NervGen completed a US$60.0 million underwritten public offering and established a new US$50.0 million ATM facility. Q2 R&D expenses rose to C$7.9 million and G&A to C$4.3 million, contributing to a net loss of C$29.2 million, including a C$19.4 million non-cash unrealized loss on warrant derivatives. The company also reported positive blinded gait analysis results from the Phase 2 CONNECT SCI study and strengthened its leadership team with a new CFO and SVP, Clinical Development.
NervGen Pharma (NASDAQ:NGEN) reported independent, blinded biomechanical gait analyses from the Phase 1b/2a CONNECT SCI study showing NVG-291 promoted statistically significant improvements in gait quality versus placebo.
NVG-291 achieved a Global Treatment Effect of +0.45 (p=0.0197), with 100% (10/10) responders vs 10% (1/10) on placebo, and consistent benefits across coordination, mechanical effort, and postural stability. According to NervGen, these data support advancing NVG-291 into the Phase 3 RESTORE registrational study in chronic tetraplegia, targeted to start mid-2026 after alignment with the FDA.
NervGen Pharma (NASDAQ:NGEN) priced an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 shares at US$2.50 per share and warrant.
Gross proceeds are expected to be about US$60.0 million, funding NVG-291 clinical studies and general corporate purposes.
NervGen (NASDAQ:NGEN) has commenced an underwritten public offering of common shares, pre-funded warrants and accompanying common share warrants. All securities will be sold by the company.
Net proceeds are intended to advance NVG-291 clinical studies and for general corporate and working capital purposes.
NervGen (NASDAQ:NGEN) reported first quarter 2026 results and business progress. Cash and investments were $16.6 million as of March 31, 2026. Q1 2026 R&D expenses were $4.9 million and G&A expenses were $2.7 million. Net loss was $1.7 million, versus $3.9 million in Q1 2025, reflecting a higher non-cash unrealized gain on a warrant derivative.
The company completed a successful FDA End-of-Phase 2 meeting, aligning on the RESTORE registrational study of NVG-291 in chronic tetraplegia, with initiation targeted for mid-2026. NervGen also advanced CONNECT SCI biomechanical gait analyses, continued pipeline expansion planning, strengthened senior leadership, and listed its shares on Nasdaq.
NervGen (NASDAQ:NGEN) appointed Keith Vendola, MD, MBA, as Chief Financial Officer, effective immediately.
Vendola will lead financial strategy, capital markets, planning and corporate development as NervGen advances NVG-291 toward initiation of the RESTORE registrational study in chronic tetraplegia. He brings two decades of finance, operational and medical experience across biopharma and investment banking.
NervGen (NASDAQ: NGEN) said its CEO Adam Rogers, MD, and executive team will participate in two investor events in April 2026: the H.C. Wainwright “HCW@Home” fireside chat on April 15, 2026 and the Bloom Burton Healthcare Investor Conference presentation and 1x1 meetings in Toronto on April 22, 2026.
Both events will offer a live webcast and archived replay; presentation formats include a virtual fireside chat and a corporate presentation with investor meetings. According to the company, webcasts will be available on the investor section of the company website.